NASDAQ:APEN - Apollo Endosurgery Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.90 -0.15 (-3.70 %) (As of 12/14/2018 02:32 PM ET)Previous Close$4.05Today's Range$3.89 - $4.1052-Week Range$3.14 - $9.65Volume2,500 shsAverage Volume49,617 shsMarket Capitalization$89.76 millionP/E Ratio-2.04Dividend YieldN/ABeta0.34 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas. Receive APEN News and Ratings via Email Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APEN Previous Symbol CUSIPN/A Webwww.apolloendo.com Phone512-279-5100 Debt Debt-to-Equity Ratio0.67 Current Ratio2.42 Quick Ratio1.81 Price-To-Earnings Trailing P/E Ratio-2.04 Forward P/E Ratio-2.19 P/E GrowthN/A Sales & Book Value Annual Sales$64.31 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book1.35 Profitability EPS (Most Recent Fiscal Year)($2.01) Net Income$-27,290,000.00 Net Margins-56.22% Return on Equity-71.73% Return on Assets-33.12% Miscellaneous Employees213 Outstanding Shares21,890,000Market Cap$89.76 million OptionableNot Optionable Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions What is Apollo Endosurgery's stock symbol? Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN." How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.11. The biotechnology company earned $14.14 million during the quarter, compared to analysts' expectations of $16.21 million. Apollo Endosurgery had a negative net margin of 56.22% and a negative return on equity of 71.73%. View Apollo Endosurgery's Earnings History. When is Apollo Endosurgery's next earnings date? Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Apollo Endosurgery. What price target have analysts set for APEN? 3 brokerages have issued twelve-month price targets for Apollo Endosurgery's shares. Their forecasts range from $3.00 to $8.00. On average, they anticipate Apollo Endosurgery's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price. View Analyst Price Targets for Apollo Endosurgery. What is the consensus analysts' recommendation for Apollo Endosurgery? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery. What are Wall Street analysts saying about Apollo Endosurgery stock? Here are some recent quotes from research analysts about Apollo Endosurgery stock: 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (11/13/2018) 2. Northland Securities analysts commented, "We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera." (2/8/2018) Has Apollo Endosurgery been receiving favorable news coverage? News headlines about APEN stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Apollo Endosurgery earned a news impact score of 1.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the near future. Who are some of Apollo Endosurgery's key competitors? Some companies that are related to Apollo Endosurgery include Neuronetics (STIM), Accuray (ARAY), Liquidia Technologies (LQDA), Utah Medical Products (UTMD), SeaSpine (SPNE), MiMedx Group (MDXG), Nuvectra (NVTR), Iradimed (IRMD), Cytosorbents (CTSO), Westaim (WEDXF), GenMark Diagnostics (GNMK), Pulse Biosciences (PLSE), T2 Biosystems (TTOO), RenovaCare (RCAR) and Alphatec (ATEC). Who are Apollo Endosurgery's key executives? Apollo Endosurgery's management team includes the folowing people: Mr. Todd Newton, CEO & Director (Age 55)Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation PartnerMr. Anthony Kalloo M.D., Co-Founder and Innovation PartnerDr. Robert Hawes M.D., Co-Founder and Innovation PartnerDr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner Who are Apollo Endosurgery's major shareholders? Apollo Endosurgery's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.15%), Vanguard Group Inc (2.15%), Dimensional Fund Advisors LP (0.53%), NJ State Employees Deferred Compensation Plan (0.53%), Manatuck Hill Partners LLC (0.49%) and EAM Investors LLC (0.40%). Company insiders that own Apollo Endosurgery stock include A/S Novo, Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Institutional Ownership Trends for Apollo Endosurgery. Which major investors are selling Apollo Endosurgery stock? APEN stock was sold by a variety of institutional investors in the last quarter, including Manatuck Hill Partners LLC and NJ State Employees Deferred Compensation Plan. View Insider Buying and Selling for Apollo Endosurgery. Which major investors are buying Apollo Endosurgery stock? APEN stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., EAM Investors LLC, Worth Venture Partners LLC, JPMorgan Chase & Co., Renaissance Technologies LLC and Dimensional Fund Advisors LP. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Insider Buying and Selling for Apollo Endosurgery. How do I buy shares of Apollo Endosurgery? Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Apollo Endosurgery's stock price today? One share of APEN stock can currently be purchased for approximately $3.90. How big of a company is Apollo Endosurgery? Apollo Endosurgery has a market capitalization of $89.76 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe. What is Apollo Endosurgery's official website? The official website for Apollo Endosurgery is http://www.apolloendo.com. How can I contact Apollo Endosurgery? Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected] MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 148 (Vote Outperform)Underperform Votes: 104 (Vote Underperform)Total Votes: 252MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?